A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia

NCT07441980 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Relapsed/Refractory Acute Myeloid Leukemia(AML)

Interventions

DRUG: CAR-T cells chimeric antigen receptor T cells

Sponsor

Institute of Hematology & Blood Diseases Hospital, China